In this white paper, we explore the reasons that have led to the decline of R&D productivity in pharma industry through a new perspective: the innovation screen and the impact of risk aversion on value generation.
Download this white paper and learn how to become a value-focused, unbiased organization and reap its benefits.
- What has happened to R&D productivity in pharma
- The biased R&D organization
- Looking through the lens of the innovation screen
- How risk aversion destroys value
- Transforming to an unbiased, value-focused organization